BIOGEN INC said its Alzheimer's drug did not meet the main goal of a mid-stage trial. The setback affects the company's neurology portfolio expansion. Drug failures can shift investor focus to other pipeline candidates.

Biogen announced on Thursday that its Alzheimer’s drug did not meet the main goal of a mid-stage trial. The results follow the completion of the study phase.
BIOGEN INC said its Alzheimer's drug did not meet the main goal of a mid-stage trial. The setback affects the company's neurology portfolio expansion. Drug failures can shift investor focus to other pipeline candidates.

Everything you use on the web — faster, and in your pocket.